Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009
l results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)... 2013 AMRI (NASDAQ: AMRI ) ... , site has received approval to expand ... to handle Schedule 2 and 2N controlled substances. ... Burlington,s physical security and quality ... (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With ...
(Date:6/18/2013)... Research and Markets ... of the report " DNA Sequencing - ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... human genome variations, development of sequencing technologies, ... sequencers are described as well as companies ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2... has been so much media attention focused on the ... finally shedding some light on the issue. Whatever the ... America to cheaper labor. The effects of this are ... It doesnt matter what you are making, whether you ...
... Among the reasons North Carolina Sen. John Edwards polled ... thinks the North American Free Trade Agreement has been a ... voters who are eager to blame the states economic troubles ... really not that short-sighted. Free trade is a part of ...
... Wis.- Gundersen Lutheran Health System is reducing surgery delays ... management of its surgical instruments and trays by using ... Minn.- based Lawson Software. , ,Gundersen Lutheran operates ... of the nation's largest group medical practices, community clinics, ...
Cached Biology Technology:Offshore outsourcing affects American workers 2Offshore outsourcing affects American workers 3A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests 2Gunderson Lutheran Implements Instrument Management Systems 2(Date:6/17/2013)... and algae, is a common component of sugar-free gum ... medical field it,s approved by the FDA as ... during surgery as a substance that opens the blood/brain ... Now Profs. Ehud Gazit and Daniel Segal of Tel ... the Sagol School of Neuroscience, along with their colleague ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further establish ... with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and ... its third year, this competition continues to grow in ... careers in basic and clinical research," said Nicholas F. ... "We are extremely proud of all that these fellows ...
(Date:6/17/2013)... Amphibian populations are declining worldwide and a major cause ... bullfrogs, but a two-year study shows they can also ... are a tolerant carrier host that just spreads the ... in controlled experimental conditions, they found at least one ... called Bd or a chytrid fungus, can be fatal ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2... more foreign children in the classroom, and many of them ... A study by the University of Gerona has assessed the ... that they take at least six years to acquire the ... system that has proven successful in other countries as a ...
... at the University of Leeds have come a step closer ... Their findings, published in the International Journal of ... developed to tackle other cancers should be considered as a ... as tamoxifen, that target a protein responsible for tumour growth, ...
... at The University of Texas Health Science Center at ... study the spread of E. coli , a ... Jennifer Juarez received fellowships from the American Society for ... The ASM fellowship supports professional development and the NIH ...
Cached Biology News:Foreign children take at least 6 years to learn the language used in school 2Foreign children take at least 6 years to learn the language used in school 3Another step toward resisting breast cancer 2UTHealth student earns fellowships to research major source of bacterial infections 2Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Human Cell Line Slides...
Human Cell Line Slides...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |